Coccidioidomycosis (Valley Fever) (Coccidioides spp.)
For the why behind the fact
Use this page to connect what you are memorizing.
Start with the overview when a class slide, Anki card, or qbank explanation feels too thin. Then use presentation and workup to recognize the condition, and differentials to separate look-alikes.
Overview
Plain-Language Overview
Coccidioidomycosis (Valley Fever) is an infection caused by breathing in spores of the fungus Coccidioides found in soil, mainly in the southwestern United States. It primarily affects the lungs, causing symptoms like cough, fever, and chest pain. Some people may experience fatigue and muscle aches, while others might have no symptoms at all. In rare cases, the infection can spread beyond the lungs to other parts of the body, such as the skin, bones, or brain, leading to more serious health problems. The illness can last for weeks to months and may require medical evaluation to confirm the diagnosis.
Clinical Definition
Coccidioidomycosis follows inhalation of soil-derived arthroconidia of Coccidioides immitis or C. posadasii. In tissue, the characteristic form is a large spherule containing endospores, rather than a budding yeast. Infection ranges from asymptomatic or self-limited pneumonia to chronic pulmonary or disseminated disease involving skin, bone, joints or meninges. Protective cell-mediated immunity helps contain infection. Erythema nodosum and early arthralgia are reactive manifestations and do not by themselves establish dissemination.
Inciting Event
Inhalation of arthroconidia spores released from disturbed soil in endemic areas.
Exposure to dust storms or soil excavation activities in endemic regions.
Occupational activities such as construction, farming, or archaeology that aerosolize fungal spores.
Travel to or residence in arid desert climates with endemic Coccidioides spp.
Latency Period
Symptoms typically develop 1 to 3 weeks after inhalation of spores.
Pulmonary symptoms may appear within 7 to 21 days post-exposure.
Disseminated disease can manifest weeks to months after initial infection.
Antibodies may not be detectable early; absence of symptoms or a negative early serologic test does not establish when exposure occurred.
Diagnostic Delay
Initial symptoms mimic community-acquired pneumonia, leading to misdiagnosis.
Lack of awareness of endemic exposure history delays suspicion.
Serologic tests may be negative early in disease, causing false reassurance.
Radiographic findings are nonspecific and often attributed to bacterial pneumonia.
Mild or asymptomatic cases do not prompt early diagnostic testing.
Clinical Presentation
Signs & Symptoms
Fever, cough, and chest pain are hallmark respiratory symptoms.
Fatigue and night sweats commonly accompany systemic illness.
Erythema nodosum presents as tender red nodules on the shins.
Symmetric arthralgia, often with erythema nodosum, is part of early desert rheumatism; persistent focal synovitis or bone pain raises concern for disseminated infection.
Weight loss and dyspnea can indicate more severe or disseminated disease.
History of Present Illness
Patients often present with fever, cough, and pleuritic chest pain progressing over days to weeks.
Constitutional symptoms include fatigue, night sweats, and weight loss.
Erythema nodosum or erythema multiforme may appear as immune-mediated skin manifestations.
Disseminated disease presents with bone pain, meningitis symptoms, or skin lesions after initial pulmonary illness.
Symptoms may fluctuate with periods of improvement and relapse.
Past Medical History
History of immunosuppressive conditions such as HIV/AIDS or organ transplantation.
Previous residence or travel to endemic areas increases pretest probability.
Prior episodes of pulmonary infections or unexplained chronic cough.
Ask about current pregnancy and recent delivery; severe disease risk is particularly increased late in pregnancy and immediately postpartum.
Use of corticosteroids or other immunosuppressants may worsen disease course.
Family History
Most infections follow environmental exposure, but rare inborn errors of cellular immunity can predispose to severe dissemination.
Familial clustering is rare but may reflect shared environmental exposures.
Known susceptibility defects include IL-12/IFN-gamma pathway abnormalities, such as IL12RB1 deficiency, and certain STAT1 gain-of-function variants.
Rare inherited immune defects have Mendelian patterns; routine cases of coccidioidomycosis are acquired infections, not a single-gene inherited disease.
Family history of immunodeficiency disorders may increase risk indirectly.
Physical Exam Findings
Fever and tachypnea are common during acute infection.
Rales or crackles may be heard on lung auscultation in pulmonary involvement.
Erythema nodosum or erythema multiforme can appear as skin manifestations.
Lymphadenopathy may be present in disseminated disease.
Chest wall tenderness can occur with pleuritic involvement.
Diagnostic Workup
Diagnostic Criteria
Combine the clinical syndrome and exposure history with serology, culture or characteristic tissue microscopy. EIA antibody results may require immunodiffusion or complement-fixation confirmation. Serology may be negative early or with immunosuppression; repeat testing or direct sampling is appropriate when suspicion persists. Endospore-containing spherules are a hallmark. Imaging is supportive but not specific. Alert the laboratory when Coccidioides is suspected because mold cultures present an inhalation hazard.
Pathophysiology
Key Mechanisms
Inhalation of airborne arthroconidia from Coccidioides spp. leads to pulmonary infection and local inflammatory response.
In tissue, arthroconidia develop into endosporulating spherules. Rupture releases endospores that can generate new spherules and provoke suppurative or granulomatous inflammation.
Cell-mediated immunity is critical for controlling infection and preventing dissemination.
Hematogenous dissemination can reach skin, bones, joints and meninges. Risk rises with impaired cellular immunity, but dissemination also occurs without recognized immunosuppression.
Erythema nodosum and early polyarthralgia reflect a reactive immune response; these lesions differ from destructive extrapulmonary sites containing viable fungi.
| Involvement | Details |
|---|---|
| Organs | Lungs are the main organ affected, presenting with pneumonia-like symptoms and possible cavitary lesions. |
Skin findings include reactive erythema nodosum or erythema multiforme. Disseminated cutaneous infection instead produces organism-containing lesions such as nodules, ulcers or verrucous plaques. | |
Central nervous system can be affected in disseminated coccidioidomycosis causing meningitis. | |
| Tissues | Pulmonary tissue is the primary site of infection where inhaled arthroconidia transform into spherules causing inflammation. |
Granulomatous tissue forms as a host response to contain fungal elements and prevent dissemination. | |
| Cells | Macrophages participate in uptake of small fungal forms and cellular immune responses. Mature spherules are too large for ordinary engulfment; do not equate them with small intracellular Histoplasma yeasts. |
T helper 1 (Th1) cells mediate protective immunity by producing interferon-gamma to activate macrophages. | |
Neutrophils contribute to early innate defense but are less effective against mature spherules. | |
| Chemical Mediators | Interferon-gamma is critical for activating macrophages to kill Coccidioides organisms. |
Tumor necrosis factor-alpha (TNF-alpha) promotes granuloma formation to contain infection. | |
Interleukin-12 (IL-12) drives differentiation of Th1 cells essential for cell-mediated immunity. |
Treatments
Pharmacological Treatments
Fluconazole
- Mechanism:
Inhibits fungal cytochrome P450 enzyme 14-alpha-demethylase, disrupting ergosterol synthesis and fungal cell membrane integrity.
- Side effects:
Hepatotoxicity
Rash; QT prolongation and drug interactions require review
Gastrointestinal upset; prolonged high-dose exposure in early pregnancy can harm fetal development
- Clinical role:
Preferred oral option when pulmonary disease warrants treatment and usual initial therapy for coccidioidal meningitis. Meningitis generally requires lifelong suppression; mild low-risk pulmonary disease may need observation only.
Itraconazole
- Mechanism:
Blocks fungal 14-alpha-demethylase, impairing ergosterol synthesis and fungal cell membrane formation.
- Side effects:
Hepatotoxicity
Heart failure exacerbation
Gastrointestinal upset
- Clinical role:
Oral option for selected pulmonary or extrapulmonary disease, often favored for bone/joint infection. Monitor absorption, levels and interactions; fluconazole is usually preferred for meningitis.
Amphotericin B
- Mechanism:
Binds ergosterol in fungal cell membranes, creating pores that cause cell death.
- Side effects:
Nephrotoxicity
Infusion-related reactions
Potassium and magnesium wasting
- Clinical role:
Initial therapy for severe or rapidly progressive nonmeningeal disease; also important when treating early-pregnancy infection. IV amphotericin alone is inadequate for meningitis; intrathecal rescue is specialist care.
Non-pharmacological Treatments
For mild improving pulmonary illness in an otherwise low-risk host, provide education, supportive care and follow-up; many patients recover without antifungals. Give oxygen for hypoxemia when needed.
Surgical consultation is appropriate for selected persistently symptomatic cavities, rupture, major hemoptysis or threatening vertebral disease; routine drainage of every large cavity is not indicated.
Assess for complications and functional recovery at follow-up. Coccidioidal meningitis with hydrocephalus may require neurosurgical CSF diversion in addition to antifungal therapy.
Prevention
Pharmacological Prevention
No established antifungal prophylaxis is routinely recommended for healthy individuals.
Use prophylaxis for defined high-risk settings, such as transplant recipients in endemic areas, under specialist guidance; it is not universal for every immunocompromised person.
Coordinate any reduction of immunosuppression with the treating specialists during severe active infection; abrupt withdrawal of essential therapy can also cause harm.
Non-pharmacological Prevention
Avoiding exposure to dusty soil in endemic areas reduces infection risk.
Reduce dust exposure and use a well-fitted N95 respirator when dusty exposure cannot be avoided; ordinary face coverings or protective clothing do not provide equivalent inhalation protection.
Public health education about endemic regions and symptoms improves early diagnosis.
Apply exposure assessment and serologic screening in selected high-risk settings, including before some immunosuppressive therapies; strategy depends on host risk and local guidance.
Outcome & Complications
Complications
Disseminated coccidioidomycosis involving skin, bones, or CNS is a serious complication.
Coccidioidal meningitis can cause hydrocephalus, vasculitic infarction and neurological deficits; it requires prolonged specialist care.
Pulmonary fibrosis can develop after severe or chronic infection.
Pleural effusion or empyema may complicate pulmonary disease.
Respiratory failure can occur in severe pulmonary involvement.
| Short-term Sequelae | Long-term Sequelae |
|---|---|
|
|
Differential Diagnoses
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) versus Histoplasmosis
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) | Histoplasmosis |
|---|---|
Exposure to arid soil in southwestern United States | Exposure to bat or bird droppings in Ohio and Mississippi River valleys |
Infiltrates, nodules, cavities and hilar/mediastinal adenopathy can occur; no single pattern is diagnostic. | Adenopathy, nodules or diffuse infiltrates may occur; imaging overlaps with other fungal infections. |
Serology in context, culture or endospore-containing spherules support diagnosis. | Urine/serum antigen can support histoplasmosis but may cross-react with Blastomyces; culture or tissue findings may help resolve uncertainty. |
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) versus Tuberculosis
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) | Tuberculosis |
|---|---|
Acute or chronic infiltrates, nodules, cavities and scarring can occur. | Upper-lobe cavitation is a classic reactivation pattern, but other patterns occur; imaging alone does not distinguish TB from fungal disease. |
Coccidioidal testing identifies the fungus; a negative AFB smear alone does not exclude concurrent TB. | Use M. tuberculosis-specific NAAT and culture. AFB smear is neither fully sensitive nor specific for M. tuberculosis. |
Often self-limited or subacute respiratory symptoms with erythema nodosum | Chronic progressive symptoms with night sweats and weight loss |
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) versus Blastomycosis
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) | Blastomycosis |
|---|---|
Classically associated with dusty soil exposure in the southwestern United States; consider the full travel history. | Soil/decaying organic matter exposure in endemic regions, including the Great Lakes and Ohio/Mississippi valleys; geography is a clue rather than an absolute boundary. |
Spherules containing endospores on microscopy | Broad-based budding yeast on microscopy |
Reactive erythema nodosum can accompany pulmonary disease; true dissemination can also involve skin, bone and meninges. | Pulmonary disease can disseminate to skin and bone, with verrucous or ulcerative lesions; morphology and targeted tests distinguish overlapping findings. |
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) versus Community-acquired bacterial pneumonia
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) | Community-acquired bacterial pneumonia |
|---|---|
Can present as acute or subacute community-acquired pneumonia with variable fever, cough and imaging. | Bacterial pneumonia also has variable clinical and radiographic patterns; abrupt onset or lobar consolidation is not required. |
Leukocyte counts and negative routine bacterial cultures do not establish a fungal diagnosis. | Neutrophilia may support inflammation, but sputum Gram stain/culture can be nondiagnostic; interpret sample quality and prior antibiotics. |
Antibacterial treatment does not target Coccidioides; many mild cases improve without antifungals, while severe or high-risk disease requires treatment. | Appropriate antibiotics generally improve bacterial disease, but delayed response has multiple causes and is not diagnostic of a fungus. |
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) versus Sarcoidosis
Coccidioidomycosis (Valley Fever) (Coccidioides spp.) | Sarcoidosis |
|---|---|
Patchy infiltrates, nodules and hilar or mediastinal adenopathy can occur. | Symmetric bilateral hilar adenopathy is characteristic, but imaging overlaps with granulomatous infections. |
Granulomatous or suppurative inflammation with characteristic spherules; necrosis alone is not the key discriminator. | Typically nonnecrotizing granulomas, with appropriate evaluation to exclude infectious and other causes. |
Interpret serology with exposure and illness; culture or tissue morphology can establish infection. | Requires compatible clinical/pathologic findings and exclusion of alternatives. Serum ACE is neither sufficiently specific nor sensitive to confirm or exclude sarcoidosis. |